Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRUGNASDAQ:GHRSNASDAQ:SANANASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRUGBright Minds Biosciences$26.58+1.8%$29.31$0.93▼$79.02$183.92M-6.01825,359 shs29,409 shsGHRSGH Research$12.72+4.3%$11.50$6.00▼$20.50$634.22M0.96194,465 shs575,106 shsSANASana Biotechnology$2.83+3.7%$2.23$1.26▼$7.40$615.55M1.853.70 million shs5.81 million shsSTOKStoke Therapeutics$11.65+2.6%$10.27$5.35▼$16.15$619.67M1.14673,599 shs466,575 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRUGBright Minds Biosciences+12.20%-3.62%+0.42%-27.69%+2,307.34%GHRSGH Research-2.01%+4.37%+1.75%+13.29%+4.55%SANASana Biotechnology-2.85%+5.00%+26.39%+82.00%-50.00%STOKStoke Therapeutics-2.41%-2.07%+18.11%+82.18%-15.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRUGBright Minds Biosciences3.2024 of 5 stars3.63.00.00.04.02.50.0GHRSGH Research1.6133 of 5 stars3.51.00.00.02.70.80.0SANASana Biotechnology2.5394 of 5 stars3.51.00.00.02.13.30.6STOKStoke Therapeutics4.009 of 5 stars3.60.00.04.82.40.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRUGBright Minds Biosciences 3.25Buy$83.25213.21% UpsideGHRSGH Research 3.00Buy$32.00151.57% UpsideSANASana Biotechnology 3.00Buy$8.60203.89% UpsideSTOKStoke Therapeutics 3.29Buy$23.2099.14% UpsideCurrent Analyst Ratings BreakdownLatest DRUG, GHRS, STOK, and SANA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.006/24/2025GHRSGH ResearchJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$39.006/24/2025SANASana BiotechnologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$5.006/4/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.005/21/2025DRUGBright Minds BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/14/2025STOKStoke TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$47.00 ➝ $35.005/13/2025DRUGBright Minds BiosciencesCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/13/2025DRUGBright Minds BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025DRUGBright Minds BiosciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/13/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRUGBright Minds BiosciencesN/AN/AN/AN/A$0.92 per shareN/AGHRSGH ResearchN/AN/AN/AN/A$3.44 per shareN/ASANASana BiotechnologyN/AN/AN/AN/A$1.12 per shareN/ASTOKStoke Therapeutics$36.56M17.40N/AN/A$4.32 per share2.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRUGBright Minds Biosciences-$2.06M-$0.36N/AN/AN/AN/A-14.56%-14.29%8/13/2025 (Estimated)GHRSGH Research-$38.96M-$0.79N/AN/AN/AN/A-19.20%-18.40%9/2/2025 (Estimated)SANASana Biotechnology-$266.76M-$0.88N/AN/AN/AN/A-86.58%-44.49%8/6/2025 (Estimated)STOKStoke Therapeutics-$88.98M$0.7914.75N/AN/A26.33%19.08%15.72%8/5/2025 (Estimated)Latest DRUG, GHRS, STOK, and SANA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q2 2025DRUGBright Minds Biosciences-$0.39-$0.29+$0.10-$0.29N/AN/A5/8/2025Q1 2025GHRSGH Research-$0.61-$0.19+$0.42-$0.19N/AN/A5/8/2025Q1 2025SANASana Biotechnology-$0.22-$0.20+$0.02-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRUGBright Minds BiosciencesN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRUGBright Minds BiosciencesN/A126.01126.01GHRSGH ResearchN/A29.7129.71SANASana BiotechnologyN/A3.403.40STOKStoke TherapeuticsN/A8.418.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRUGBright Minds Biosciences40.52%GHRSGH Research56.90%SANASana Biotechnology88.23%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipDRUGBright Minds Biosciences42.66%GHRSGH ResearchN/ASANASana Biotechnology31.10%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableGHRSGH Research1052.03 millionN/AOptionableSANASana Biotechnology380225.48 million155.35 millionOptionableSTOKStoke Therapeutics10054.60 million49.41 millionOptionableDRUG, GHRS, STOK, and SANA HeadlinesRecent News About These CompaniesStoke Therapeutics' (STOK) "Buy" Rating Reaffirmed at Needham & Company LLCJuly 1 at 8:40 AM | marketbeat.comMichelin’s Stoke-on-Trent plant set to lower CO2 emissions with tyre reprocessing siteJuly 1 at 3:34 AM | thebusinessdesk.comTStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Buy" from AnalystsJune 30 at 2:29 AM | marketbeat.comSTOK Stoke Therapeutics, Inc. - Seeking AlphaJune 29 at 9:44 AM | seekingalpha.comAnalysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Legend Biotech (LEGN)June 28 at 3:13 PM | theglobeandmail.comStoke-on-Trent bungalow could be turned into children's homeJune 28 at 10:12 AM | msn.comStoke City confirm new coach appointment as pre-season startsJune 27, 2025 | msn.comTraditional Stoke-on-Trent pub reopens for the first time since CovidJune 27, 2025 | stokesentinel.co.ukSStoke Therapeutics (NASDAQ:STOK) Trading Down 3.5% - Here's WhyJune 26, 2025 | marketbeat.comStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 17, 2025 | businesswire.comSTOK FY2025 EPS Forecast Lowered by Cantor FitzgeraldJune 16, 2025 | marketbeat.comStoke Therapeutics: Impressive Pipeline And Big BackersJune 15, 2025 | seekingalpha.comAssenagon Asset Management S.A. Sells 391,322 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)June 15, 2025 | marketbeat.comCantor Fitzgerald Predicts STOK FY2026 EarningsJune 10, 2025 | marketbeat.comKangaroo Care Awareness Day celebrated at Stoke Mandeville HospitalJune 10, 2025 | msn.comJong Oranje and Stoke City star is open to transfer: “Of course, I have my ambitions”June 10, 2025 | sports.yahoo.comStoke City confirm next stage of major badge consultationJune 10, 2025 | msn.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)June 10, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Two Sigma Investments LPJune 9, 2025 | marketbeat.comJane Street Group LLC Sells 318,465 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)June 8, 2025 | marketbeat.comStoke City Secure Youth International Amid Leeds United InterestJune 7, 2025 | therealefl.co.ukTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonWith Novo Nordisk's CEO Out, Wall Street Wants an American LeaderBy Leo Miller | June 7, 2025View With Novo Nordisk's CEO Out, Wall Street Wants an American LeaderAnalysts Can't Get Enough of These Little-Known Biopharma StocksBy Nathan Reiff | June 12, 2025View Analysts Can't Get Enough of These Little-Known Biopharma StocksNektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?By Leo Miller | June 28, 2025View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIABy Leo Miller | June 12, 2025View IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIADRUG, GHRS, STOK, and SANA Company DescriptionsBright Minds Biosciences NASDAQ:DRUG$26.58 +0.47 (+1.80%) Closing price 04:00 PM EasternExtended Trading$25.84 -0.73 (-2.77%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.GH Research NASDAQ:GHRS$12.72 +0.53 (+4.35%) Closing price 04:00 PM EasternExtended Trading$12.74 +0.01 (+0.12%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Sana Biotechnology NASDAQ:SANA$2.83 +0.10 (+3.66%) Closing price 04:00 PM EasternExtended Trading$2.85 +0.02 (+0.85%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Stoke Therapeutics NASDAQ:STOK$11.65 +0.30 (+2.64%) Closing price 04:00 PM EasternExtended Trading$11.38 -0.27 (-2.32%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
